Investigation of osteosarcoma genomics and its impact on targeted therapy: An international collaboration to conquer human osteosarcoma

Chinese Journal of Cancer

Volumn 33, Issue 12, 2014, Pages 575-580

  Yang, Ji Long ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

ACGH; APEX1 gene; KCNMB4 CCND3 fusion gene; LRP1 SNRNP25 fusion gene; Osteosarcoma; RUNX2 gene; The VEGF pathway; The Wnt pathway; Transcriptome sequencing; WWOX gene

Indexed keywords

APEX1 PROTEIN, HUMAN; DNA (APURINIC OR APYRIMIDINIC SITE) LYASE;

ADULT; BONE TUMOR; CHILD; CHINA; COMPARATIVE GENOMIC HYBRIDIZATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; GENOMICS; HUMAN; MOLECULARLY TARGETED THERAPY; OSTEOSARCOMA; PROGNOSIS; WNT SIGNALING PATHWAY; YOUNG ADULT;

ADULT; BONE NEOPLASMS; CHILD; CHINA; COMPARATIVE GENOMIC HYBRIDIZATION; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; GENOMICS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MOLECULAR TARGETED THERAPY; OSTEOSARCOMA; PROGNOSIS; WNT SIGNALING PATHWAY; YOUNG ADULT;

EID: 84914150923     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.014.10209     Document Type: Editorial

References (33)

1. [1] Yang J, Yang D, Sun Y, et al. Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma. Cancer, 2011, 117:4925-4938.
2. [2] Yang JL, Zhang W. New molecular insights into osteosarcoma targeted therapy. Curr Opin Oncol, 2013, 25:398-406.
3. [3] Yang W, Guan L. Bridging the US and China together to conquer cancer: report of the 4th Annual Meeting of the US Chinese Anti- Cancer Association (USCACA). Chin J Cancer, 2012, 31:315-318.
4. [4] Shi M, Yang W, Qian P, et al. The USCACA hosted symposiums at the 7th CACA annual meeting and the 15th CSCO annual meeting in Beijing. Chin J Cancer, 2012, 31:505-506.
5. [5] Guan L, Dai Y, Luo R. Translational research in oncology research & development and its impact on early development in China: report of the 5th Annual Meeting of the US Chinese Anti-Cancer Association (USCACA) at 2013 AACR Annual Meeting. Chin J Cancer, 2013, 32:357-362.
6. [6] Yang J, Zhao L, Tian W, et al. Correlation of WWOX, RUNX2 and VEGFA protein expression in human osteosarcoma. BMC Med Genomics, 2013, 6:56.
7. [7] Yang J, Zhang W. New molecular insights into osteosarcoma targeted therapy. Curr Opin Oncol, 2013, 25:398-406.
8. [8] Yang J, Zhang W. WWOX tumor suppressor gene. Histol Histopathol, 2008, 23:877-882.
9. [9] Yang J, Yang D, Cogdell D, et al. APEX1 gene amplification and its protein overexpression in osteosarcoma: correlation with recurrence, metastasis, and survival. Technol Cancer Res Treat, 2010, 9:161-169.
10. [10] Yang J, Cogdell D, Yang D, et al. Deletion of the WWOX gene and frequent loss of its protein expression in human osteosarcoma. Cancer Lett, 2010, 291:31-38.
11. [11] Duo J, Wang G, Han X, et al. APE1 gene silencing promotes the sensitivity of osteosarcoma U2-OS cells to bortezomib. Zhongguo Zhong Liu Lin Chuang, 2012, 39:429-432. [in Chinese]
12. [12] Du X, Yang J, Yang D, et al. The genetic basis for inactivation of wnt pathway in human osteosarcoma. BMC Cancer, 2014, 14:450.
13. [13] Yang J, Annala M, Ji P, et al. Recurrent LRP1-SNRNP25 and KCNMB4-CCND3 fusion genes promote tumor cell motility in human osteosarcoma. J Hematol Oncol, 2014, 7:76.
14. [14] Fletcher CDM, Bridge JA, Hogendoorn PCW, et al. World Health Organization classification of tumours of soft tissue and bone. 4th edition. Lyon: IARC Press, 2013.
15. [15] Zhang W, Cheng SY, Hou LF, et al. Genomics in personalized cancer medicine and its impact on early drug development in China: report from the 6th Annual Meeting of the US Chinese Anti- Cancer Association (USCACA) at the 50th ASCO Annual Meeting. Chin J Cancer, 2014, 33:371-375.
16. [16] Takaki T, Echalier A, Brown NR, et al. The structure of CDK4/cyclin D3 has implications for models of CDK activation. Proc Natl Acad Sci U S A, 2009, 106:4171-4176.
17. [17] Mejia-Guerrero S, Quejada M, Gokgoz N, et al. Characterization of the 12q15 MDM2 and 12q13-14 CDK4 amplicons and clinical correlations in osteosarcoma. Genes Chromosomes Cancer, 2010, 49:518-525.
18. [18] Sun Y, Sun B, Wang J, et al. Prognostic implication of SYT-SSX fusion type and clinicopathological parameters for tumor-related death, recurrence, and metastasis in synovial sarcoma. Cancer Sci, 2009, 100:1018-1025.
19. [19] Missiaglia E, Williamson D, Chisholm J, et al. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J Clin Oncol, 2012, 30:1670-1677.
20. [20] Debelenko LV, McGregor ML, Shivakumar BR, et al. A novel EWSR1-CREB3L1 fusion transcript in a case of small cell osteosarcoma. Genes Chromosomes Cancer, 2011, 50:1054-1062.
21. [21] Butrynski JE, D'Adamo DR, Hornick JL, et al. Crizotinib in ALKrearranged inflammatory myofibroblastic tumor. N Engl J Med, 2010, 363:1727-1733.
22. [22] Barretina J, Taylor BS, Banerji S, et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet, 2010, 42:715-721.
23. [23] Taylor BS, Barretina J, Maki RG, et al. Advances in sarcoma genomics and new therapeutic targets. Nat Rev Cancer, 2011, 11:541-557.
24. [24] Pellin A, Boix-Ferrero J, Carpio D, et al. Molecular alterations of the RB1, TP53, and MDM2 genes in primary and xenografted human osteosarcomas. Diagn Mol Pathol, 1997, 6:333-341.
25. [25] Ito M, Barys L, O'Reilly T, et al. Comprehensive mapping of p53 pathway alterations reveals an apparent role for both SNP309 and MDM2 amplification in sarcomagenesis. Clin Cancer Res, 2011, 17:416-426.
26. [26] Lonardo F, Ueda T, Huvos AG, et al. p53 and MDM2 alterations in osteosarcomas: correlation with clinicopathologic features and proliferative rate. Cancer, 1997, 79:1541-1547.
27. [27] Squire JA, Pei J, Marrano P, et al. High-resolution mapping of amplifications and deletions in pediatric osteosarcoma by use of CgH analysis of cDNA microarrays. Genes Chromosomes Cancer, 2003, 38:215-225.
28. [28] Cai Y, Cai T, Chen Y. Wnt pathway in osteosarcoma, from oncogenic to therapeutic. J Cell Biochem, 2014, 115:625-631.
29. [29] Cai Y, Mohseny AB, Karperien M, et al. Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma. J Pathol, 2010, 220:24-33.
30. [30] Aqeilan RI, Trapasso F, Hussain S, et al. Targeted deletion of Wwox reveals a tumor suppressor function. Proc Natl Acad Sci U S A, 2007, 104:3949-3954.
31. [31] Kurek KC, Del Mare S, Salah Z, et al. Frequent attenuation of the WWOX tumor suppressor in osteosarcoma is associated with increased tumorigenicity and aberrant RUNX2 expression. Cancer Res, 2010, 70:5577-5586.
32. [32] Zhao LR, Zheng H, Yang JL, et al. Gene amplification of RUNX2 and its frequent protein expression in human osteosarcoma. Zhongguo Zhong Liu Lin Chuang, 2013, 40:398-402. [in Chinese]
33. [33] Aqeilan RI, Hassan MQ, de Bruin A, et al. The WWOX tumor suppressor is essential for postnatal survival and normal bone metabolism. J Biol Chem, 2008, 283:21629-21639.